{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "0f4dddf2e7af9e771bad4a8b1f0aff71",
    "title": "Morgan Stanley | RESEARCH",
    "source_uri": "25.9月 普通个人版/9.2 普通个人版/MS/Pernod Ricard SA Questions for ManagementPernod Ricard SA Questions for Management_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:55:27.997003",
      "extracted_at": "2025-10-27T00:55:27.997009"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 8,
        "successful_pages": 8,
        "date": "2025-08-29",
        "publication": "25.9月 普通个人版/9.2 普通个人版/MS",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 3,
          "removed_paragraphs": 7,
          "reduction_ratio": 0.15631287109279157
        },
        "input_relative_path": "25.9月 普通个人版/9.2 普通个人版/MS"
      }
    }
  },
  "passages": [
    {
      "passage_id": "9388966fa384dee4",
      "text": "August 29, 2025 03:21 AM GMT",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a7b97bdbba0e6732",
      "text": "Following publication of full year 2025 results on August 28th, we set out key points that investors may want to discuss with management",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ccbf451a7efb5b9b",
      "text": "1. US: the unwind of the pre-tariff inventory build at distributors did not occur as fast as was originally envisaged. Can you quantify how big that overhang is, and why you expect it to unwind over the course of the fiscal year as opposed to simply in Q1 2026.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "161311f71586ff24",
      "text": "2. China: you have flagged that inventory levels are high, reflecting the fact that customers acquired stock ahead of the change in minimum pricing (which could have caused logistical issues). How big is this stock overhang, and what do you think the underlying rate of decline in end demand actually was in Q4. Has the market weakened further since then (on an underlying basis?). Why do you think this inventory unwind will occur fully in Q1 2026 (as opposed to through the year as in the US)?",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c9e97252bf4b2d17",
      "text": "3. India: you have indicated that you expect the magnitude of the impact on demand (of the changes to excise duties in Maharashtra) to moderate as the year goes on. Can you provide examples of where consumers adapted to a price increase as large as this? India grew at 6% in FY25: do you think that this is a reasonable rate of growth to assume for the non-Maharashtra states to grow?",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "214d7731147cea1c",
      "text": "4. RTDs: like peer Diageo, you have stated an intention to grow this business more aggressively. In prior periods, spirits companies were less positive on this category. What has changed your mind? At scale, what kind of margin do you think RTDs could generate?",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "be80cf1a755c9c0c",
      "text": "5. Disposals: the company has sold the wine portfolio and reached agreement on Imperial Blue and some small, Lishik whisky brands. Are there other assets that you now view as non-core? You've said that these disposals will be margin accretive, but given you are selling assets in a soft market, are you achieving sufficiently high value to offset the loss of earnings?",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "833d79e775fbe200",
      "text": "6. Tariffs: in FY25 you were provisioning for China tariffs in the P&L. Now that the threat of tariffs has gone, replaced with minimum pricing, what has happened to the P&L charge? What was the total quantum of the charge, and did you reverse it in H2 such that FY25 had no such provision? Meanwhile, you have lowered your estimate for the impact of US tariffs from €60-70m to €35m. However, the original figure was calculated on the basis of a 10% tariff rate, while the agreed rate for Europe is 15%, so why has the impact not increased? Does the €35m include the benefit of any stock already in the US which is not subject to tariffs and will therefore mitigate the charge in FY26?",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "59ca68befecabe3c",
      "text": "7. Strategic investments: you have stated that strategic investment in maturing liquid and capex will be lower than €900m in FY26, and that the mid-term level",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "84422b651943ef50",
      "text": "MORGAN STANLEY & CO. INTERNATIONAL PLC+",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "80ca5630d4a38cea",
      "text": "Pernod Ricard SA (PER.PPA, RI FP)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b3b848d4a5fa0d05",
      "text": "Beverages | FranceStock RatingEqual-weightIndustry ViewIn-LinePrice target€90Shr price, close (Aug 28, 2025)€10052-Week Range€141-83Mkt cap, curr (mn)€25,197Net debt (06/26e) (mn)*€9,802EV, curr (mn)*€37,222",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b566320ceb975507",
      "text": "\\* = GAAP or approximated based on GAAP",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "17de27ecb0f7c66d",
      "text": "Fiscal Year Ending06/2506/26e06/27e06/28eEPS (€)**7.906.846.036.24Prior EPS (€)**----EPS (€)7.036.566.887.12P/E**10.714.716.616.1Sales / Revenue11,59610,8319,89010,155(€mn)**EBITDA (€mn)**3,5573,2902,9473,045EBIT (€mn)**3,1162,8532,5162,591EV/EBITDA**9.311.012.211.8FCF yld ratio (%)4.23.65.25.2DPS (€)4.704.704.704.70Div yld (%)5.64.74.74.7ROE (%)**12.711.08.99.1Net debt (€mn)**10,9769,8029,7299,638Net debt/EBITDA**3.13.03.33.2",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "42bbeb2b268e1051",
      "text": "Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework \\(\\S =\\) Consensus data is provided by Refinitiv Estimates \\\\*\\\\* = Based on consensus methodology \\\\* = GAAP or approximated based on GAAP e = Morgan Stanley Research estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "92ac77d9f8878880",
      "text": "Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c4ac1dff6de0595c",
      "text": "\\(+ =\\) Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f3f518bdb81dd89a",
      "text": "should be no more than €1bn per annum. What volume growth assumption is this based upon? If the consumer is premiumising, does this imply a shift towards more matured liquids which could require you to accelerate investment in this regard?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7f7dd79851a9d1b9",
      "text": "8. Moderation: you have stated, like many of your peers, that you anticipate consumers to \"drink less but better\". How do you explain the much stronger rate of growth (both volumes and revenue) for 0.0 drinks, and for CSDs? Do you believe that premiumisation will fully offset lower volumes i.e. do you expect an acceleration in premiumisation vs history?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d5ed54ebdf43e010",
      "text": "9. Working capital: you have stated that this will remain a focus for the group in FY26. In FY25, you succeeded in reducing \"other inventories\" by nearly €300m. What was behind this, and is this a sustainable level, or could it be further improved upon?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "8d8479cbc90bfb9d",
      "text": "10. Dividend: you held your dividend flat, although you did not generate sufficient free cash flow to cover the payment, resulting in rising leverage. This appears likely to be an issue also in FY26. At what point do you consider cutting the dividend (for which you do not appear to be getting the valuation credit) and focus on accelerating debt paydown?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "1554ccd1ffc0165b",
      "text": "11. Acquisitions: the balance sheet obviously limits what you can do currently, but if you had the opportunity, would you be interested in acquiring assets in the non-alc space e.g. mixers, CSDs, functional drinks? How long are your partnership deals with third party brands e.g. Sprite, Dole?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "287b1a874d1425ac",
      "text": "Our price target is the rounded average of our P/E and DCF valuations. Our P/E approach values the stock at €88, applying a multiple of \\(\\sim 14.5x\\) CY26e P/E, at a \\(- 10\\%\\) discount to European staples given the weak growth outlook over the next \\(\\sim 12M\\) . Our DCF valuation is €92 (WACC \\(8\\%\\) , terminal growth rate \\(2.5\\%\\) ).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2f66083254395e1e",
      "text": "- Swift recovery in China as economy improves- EM penetration and premiumisation potential (especially China/India)- Significant cost-saving initiatives- Value-accretive M&A",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "bac883cc2fc9dbe1",
      "text": "- Macroeconomic downturn and consumer downtrading- China remains softer for longer- Supply-chain disruptions impacting sales / production- Continued share loss in the US market- Change in regulations and tariffs",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7ce1d09cbf7fcf26",
      "text": "The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Europe S.E., regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) and/or Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Morgan Stanley & Co. International plc disseminates in the UK research that it has prepared, and which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the \"Order\"), (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. As used in this disclosure section, Morgan Stanley includes RMB Morgan Stanley Proprietary Limited, Morgan Stanley Europe S.E., Morgan Stanley & Co International plc and its affiliates.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b436a1e255d22653",
      "text": "For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "92abebc3870bd483",
      "text": "For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303- 2495; Hong Kong +852 2848- 5999; Latin America +1 718 754- 5444 (U.S.); London +44 (0)20- 7425- 8169; Singapore +65 6834- 6860; Sydney +61 (0)2- 9770- 1505; Tokyo +81 (0)3- 6836- 9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2a1cc91a483dfdd4",
      "text": "Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict policies. A Portuguese version of the policy can be found at www.morganstanley.com.br",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a9cb2e78886a3136",
      "text": "As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Carlsberg A/S, Diageo PLC, Fevertree Drinks PLC, Pernod Ricard SA, Remy Cointreau SA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "33398705e0aa8c1e",
      "text": "Within the last 12 months, Morgan Stanley managed or co- managed a public offering (or 144A offering) of securities of Diageo PLC.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7c2217e3438405b9",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Diageo PLC, Pernod Ricard SA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8b7eda65410cf8b2",
      "text": "In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Anheuser- Busch InBev SA, Carlsberg A/S, Davide Campari Milano NV, Diageo PLC, Fevertree Drinks PLC, Heineken NV, Pernod Ricard SA, Remy Cointreau SA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3d9e30fd02122dd4",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Anheuser- Busch InBev SA, Diageo PLC, Pernod Ricard SA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "cdd9574d37ee0221",
      "text": "Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Anheuser- Busch InBev SA, Carlsberg A/S, Davide Campari Milano NV, Diageo PLC, Fevertree Drinks PLC, Heineken NV, Pernod Ricard SA, Remy Cointreau SA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "15304d3630fff78c",
      "text": "Within the last 12 months, Morgan Stanley has either provided or is providing non- investment banking, securities- related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Anheuser- Busch InBev SA, Davide Campari Milano NV, Diageo PLC, Pernod Ricard SA.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3cf6b548bbfd97c9",
      "text": "The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9930a691507c4722",
      "text": "Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "136cfc4be03696e5",
      "text": "Certain disclosures listed above are also for compliance with applicable regulations in non- US jurisdictions.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7905d743df1c7422",
      "text": "Morgan Stanley uses a relative rating system using terms such as Overweight, Equal- weight, Not- Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "99ef1d85987d7f40",
      "text": "(as of July 31, 2025)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "466ff96e59d703d1",
      "text": "The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal- weight, Not- Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal- weight and Not- Rated to hold and Underweight to sell recommendations, respectively.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "92c76a999eff7f82",
      "text": "Coverage UniverseInvestment Banking Clients (IBC)Other Material Investment Services Clients (MISC)Stock Rating CategoryCount% of TotalCount% of Total IBC% of Rating CategoryCount% of Total Other MISCOverweight/Buy149540%37845%25%70141%Equal-weight/Hold160743%37445%23%76645%Not-Rated/Hold50%00%0%20%Underweight/Sell58816%8310%14%23614%Total3,6958351705",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9c82cce025012b39",
      "text": "Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the % of total' column may not add up to exactly 100 percent.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a95ed9baaefce862",
      "text": "Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "00ce232b08a7d8e7",
      "text": "Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6fa93a812ebfcce0",
      "text": "Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6fcf4206e367cdd4",
      "text": "Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3f080271c3df4501",
      "text": "Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "94682132b4741fe5",
      "text": "Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "523f84a0500bc136",
      "text": "In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia -relevant MSCI country index or MSCI ac Asia Pacific ex Japan Index.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "389f71a1aa7755d3",
      "text": "Pernod Ricard SA (PERP.PA) - As of 08/28/25 GMT in EUR Industry : Beverages",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "934024b4fc785232",
      "text": "Stock Rating History: 8/1/20 : E/I; 11/27/20 : 0/A; 1/17/22 : 0/I; 7/24/23 : E/I Price Target History: 4/27/20 : 126; 9/3/20 : 130; 10/5/20 : 132; 10/22/20 : 135; 11/27/20 : 180; 2/12/21 : 182; 4/22/21 : 187; 7/8/21 : 205; 9/6/21 : 215; 10/27/21 : 225; 1/6/22 : 240; 4/1/22 : 230; 5/16/22 : 220; 6/28/22 : 207; 9/5/22 : 212; 10/21/22 : 203; 1/5/23 : 210; 2/20/23 : 220; 4/18/23 : 230; 7/20/23 : 205; 9/15/23 : 184; 10/2/23 : 179; 10/19/23 : 178; 1/8/24 : 155; 2/19/24 : 159; 3/19/24 : 158; 4/8/24 : 151; 4/25/24 : 152; 7/3/24 : 142; 9/13/24 : 129; 10/23/24 : 123; 11/29/24 : 115; 12/20/24 : 118;",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "44bf669c9ae35f7c",
      "text": "Source: Morgan Stanley Research Date Format: MM/DD/YY Price Target - - No Price Target Assigned (NR) Stock Price (Not Covered by Current Analyst) - - Stock Price (Covered by Current Analyst) Stock and Industry Ratings (abbreviations below) appear as Stock Rating/Industry View Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NR) Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR) Effective January 13, 2014, the stocks covered by Morgan Stanley Pacific will be rated relative to the analyst's industry (or industry team's) coverage. Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "e799877c7aec0c3d",
      "text": "Morgan Stanley Research policy is to update research reports and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1da9fedf26c9015b",
      "text": "Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd- Frank Wall Street Reform and Consumer Protection Act.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c545e1255bc027ff",
      "text": "Morgan Stanley produces an equity research product called a \"Tactical Idea.\" Views contained in a \"Tactical Idea\" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "88d830a09d975006",
      "text": "Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third- party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "07dfb1a7bf63ab7a",
      "text": "Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html).",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9090178ede6b93fe",
      "text": "If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "7eb696a138f8a8c5",
      "text": "may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "611a239b2aed7897",
      "text": "The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts, strategists or economists compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "62c74f077f01b12c",
      "text": "The \"Important Regulatory Disclosures on Subject Companies\" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns \\(1\\%\\) or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than \\(1\\%\\) in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ad5fe4a1786b4946",
      "text": "With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0f9603e82f1c9ee6",
      "text": "Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre- approved by authorized members of Research management.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "39b85c37d1466538",
      "text": "Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0c20a685c2efd0bd",
      "text": "To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited (\"MSTL\"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non- customer reader within the scope of Article 7- 1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "524bf3326660ca2b",
      "text": "Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "450f50b03524dea7",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a1ba7ed86f87e4f9",
      "text": "the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0b981ddf8b9babfb",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3ed15de9ebed0765",
      "text": "As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "7e1444ebe540a23c",
      "text": "The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "a8143a46df89ab10",
      "text": "Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework. The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "e6a39ac73fd5d85d",
      "text": "Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6de1465c7fd4049c",
      "text": "COMPANY (TICKER)RATING (AS OF)PRICE* (08/28/2025)Rashad KawanFevertree Drinks PLC (FEVR.L)E (09/22/2020)824pSarah SimonAnheuser-Busch InBev SA (ABI.BR)O (07/20/2023)€53.76Anheuser-Busch InBev SA (BUD.N)O (07/20/2023)US$62.79Carlsberg A/S (CARLb.CO)O (01/20/2025)DKr 783.60Diageo PLC (DEON)U (07/20/2023)US$112.03Diageo PLC (DGE.L)U (07/20/2023)2,063pHeineken NV (HEIN.AS)E (10/11/2023)€69.72Pernod Ricard SA (PER.PPA)E (07/20/2023)€100.40Tilly EnoDavide Campari Milano NV (CPRI.MI)E (08/12/2025)€6.57Remy Cointreau SA (RCOPPA)U (07/22/2025)€54.65",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2c822e9ca315a295",
      "text": "Stock Ratings are subject to change. Please see latest research for each company. \\\\* Historical prices are not split adjusted.",
      "page": 7,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "5dc8f59a60c48918",
      "name": "ADGM Branch",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ed49291dd8535b70",
      "name": "Abu Dhabi",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a9935cd77e910646",
      "name": "America Index",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f8e0021b3bbbd49d",
      "name": "Analyst\n\nChris",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e8600890357193e9",
      "name": "Analyst Industry",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "264f4569dd91d68d",
      "name": "Analyst Stock",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ebc1f6a39f03ec8",
      "name": "Asia Pacific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8e7a2c6365235da8",
      "name": "Associate\n\nPernod",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dcdb1ce3d269dd08",
      "name": "Associate\n\nRichard",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2dc0b3cae28d805e",
      "name": "Busch InBev",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9ded53a04124b195",
      "name": "CFA\n\nResearch",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "98bf4640b315d632",
      "name": "Capital Markets",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "27a2a88e2e1da13d",
      "name": "Centre Regulatory",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c184cb2eaab39cb8",
      "name": "Client Support",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "73ef27210d711790",
      "name": "Co International",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c8c0d67137b1b25c",
      "name": "Conflict Management",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c4d57fb1d13e1cae",
      "name": "Consumer Protection",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "870edbe8e02ee39e",
      "name": "Coverage Universe",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8d0112d1935cb728",
      "name": "Current Analyst",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dd23d5c75d42815c",
      "name": "DIFC Branch",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 2,
        "axes": null,
        "series": [],
        "figure_id": "5a5982c8591f9c9b",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "line",
        "title": "Industry: Beverages",
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Aug 2022",
              "Sep 2022",
              "Oct 2022",
              "Nov 2022",
              "Dec 2022",
              "Jan 2023",
              "Feb 2023",
              "Mar 2023",
              "Apr 2023",
              "May 2023",
              "Jun 2023",
              "Jul 2023",
              "Aug 2023",
              "Sep 2023",
              "Oct 2023",
              "Nov 2023",
              "Dec 2023",
              "Jan 2024",
              "Feb 2024",
              "Mar 2024",
              "Apr 2024",
              "May 2024",
              "Jun 2024",
              "Jul 2024",
              "Aug 2024",
              "Sep 2024",
              "Oct 2024",
              "Nov 2024",
              "Dec 2024",
              "Jan 2025",
              "Feb 2025",
              "Mar 2025",
              "Apr 2025",
              "May 2025",
              "Jun 2025",
              "Jul 2025",
              "Aug 2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 300
            }
          }
        },
        "series": [
          {
            "name": "Red Dashed Line",
            "unit": null,
            "values": [
              207,
              212,
              203,
              210,
              220,
              230,
              205,
              184,
              179,
              178,
              155,
              159,
              150,
              151,
              152,
              142,
              129,
              123,
              115,
              118,
              103,
              98,
              98
            ]
          }
        ],
        "figure_id": "927ee84f54ead592",
        "provenance": {
          "page": 6
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "45c59978b3fd0efa",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "you provide examples of where consumers adapted to a price increase as large as this? India grew at 6% in FY25: do you think that this is a reasonable rate of growth to assume for the non-Maharashtra ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "3159ffd8e4560d08",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t of US tariffs from €60-70m to €35m. However, the original figure was calculated on the basis of a 10% tariff rate, while the agreed rate for Europe is 15%, so why has the impact not increased? Does ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ecead5b7db3f0796",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "iginal figure was calculated on the basis of a 10% tariff rate, while the agreed rate for Europe is 15%, so why has the impact not increased? Does the €35m include the benefit of any stock already in ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ff43ce3efc259323",
        "value": 60.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "had no such provision? Meanwhile, you have lowered your estimate for the impact of US tariffs from €60-70m to €35m. However, the original figure was calculated on the basis of a 10% tariff rate, while",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "57a6df8e4773b3e5",
        "value": 35.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "h provision? Meanwhile, you have lowered your estimate for the impact of US tariffs from €60-70m to €35m. However, the original figure was calculated on the basis of a 10% tariff rate, while the agree",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0725c6f82de866cd",
        "value": 35.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "tariff rate, while the agreed rate for Europe is 15%, so why has the impact not increased? Does the €35m include the benefit of any stock already in the US which is not subject to tariffs and will the",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8b52f4846cc3c0e0",
        "value": 900.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "estments: you have stated that strategic investment in maturing liquid and capex will be lower than €900m in FY26, and that the mid-term level MORGAN STANLEY & CO. INTERNATIONAL PLC+ Sarah Simon Equit",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1fe83208aad05367",
        "value": 90.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "></tr><tr><td>Industry View</td><td></td><td>In-Line</td></tr><tr><td>Price target</td><td></td><td>€90</td></tr><tr><td>Shr price, close (Aug 28, 2025)</td><td></td><td>€100</td></tr><tr><td>52-Week ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7cac6dd98195263e",
        "value": 100.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "Price target</td><td></td><td>€90</td></tr><tr><td>Shr price, close (Aug 28, 2025)</td><td></td><td>€100</td></tr><tr><td>52-Week Range</td><td></td><td>€141-83</td></tr><tr><td>Mkt cap, curr (mn)</td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b259c2a36d02c5df",
        "value": 141.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "r price, close (Aug 28, 2025)</td><td></td><td>€100</td></tr><tr><td>52-Week Range</td><td></td><td>€141-83</td></tr><tr><td>Mkt cap, curr (mn)</td><td></td><td>€25,197</td></tr><tr><td>Net debt (06/2",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "65000049c64f6115",
        "value": 25197.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "<tr><td>52-Week Range</td><td></td><td>€141-83</td></tr><tr><td>Mkt cap, curr (mn)</td><td></td><td>€25,197</td></tr><tr><td>Net debt (06/26e) (mn)*</td><td></td><td>€9,802</td></tr><tr><td>EV, curr (",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "eb5cf07be0329b9f",
        "value": 9802.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "t cap, curr (mn)</td><td></td><td>€25,197</td></tr><tr><td>Net debt (06/26e) (mn)*</td><td></td><td>€9,802</td></tr><tr><td>EV, curr (mn)*</td><td></td><td>€37,222</td></tr></table> \\* = GAAP or appro",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8721cd0d568bf878",
        "value": 37222.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "td>Net debt (06/26e) (mn)*</td><td></td><td>€9,802</td></tr><tr><td>EV, curr (mn)*</td><td></td><td>€37,222</td></tr></table> \\* = GAAP or approximated based on GAAP <table><tr><td>Fiscal Year Ending<",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1bca6e64737bcc6e",
        "value": 1.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "should be no more than €1bn per annum. What volume growth assumption is this based upon? If the consumer is premiumising, doe",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "24c746a997703a08",
        "value": 300.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "ain a focus for the group in FY26. In FY25, you succeeded in reducing \"other inventories\" by nearly €300m. What was behind this, and is this a sustainable level, or could it be further improved upon? ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "0ba0778c3ea14150",
        "value": 88.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "e target is the rounded average of our P/E and DCF valuations. Our P/E approach values the stock at €88, applying a multiple of \\(\\sim 14.5x\\) CY26e P/E, at a \\(- 10\\%\\) discount to European staples g",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b0bc5b0baa69967f",
        "value": 92.0,
        "unit": "€",
        "metric_type": "currency",
        "context": "to European staples given the weak growth outlook over the next \\(\\sim 12M\\) . Our DCF valuation is €92 (WACC \\(8\\%\\) , terminal growth rate \\(2.5\\%\\) ). ## Risks to Upside - Swift recovery in China a",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fcfd3327a89063fb",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Regulatory Disclosures on Subject Companies As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanle",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "98de6c3bfe313c4c",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ry</td><td>Count</td><td>% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2c85570bee411fcf",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a56299b008e0a18e",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1cc500e7305941c3",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a7c0e9f28c587e7f",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "2d4cb90f515c71b3",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "384fe8b510b64445",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "656faf7cdd56c68a",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "801912483d0dea3e",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>58",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "56f7acde921904e0",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4cd16c502000fc11",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "e84afd5c8046dc13",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "dfdccc2b22e871c8",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695<",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "cbd9a9ee3664102c",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8ef516460673204d",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c3036a8f61ddeaf8",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><td></td><td>1705</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5510a42d64f771e0",
        "value": 53.76,
        "unit": "€",
        "metric_type": "currency",
        "context": "</td><td></td><td></td></tr><tr><td>Anheuser-Busch InBev SA (ABI.BR)</td><td>O (07/20/2023)</td><td>€53.76</td></tr><tr><td>Anheuser-Busch InBev SA (BUD.N)</td><td>O (07/20/2023)</td><td>US$62.79</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "956ccc5352ff5879",
        "value": 62.79,
        "unit": "$",
        "metric_type": "currency",
        "context": "3)</td><td>€53.76</td></tr><tr><td>Anheuser-Busch InBev SA (BUD.N)</td><td>O (07/20/2023)</td><td>US$62.79</td></tr><tr><td>Carlsberg A/S (CARLb.CO)</td><td>O (01/20/2025)</td><td>DKr 783.60</td></tr>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "19c130e6edd21920",
        "value": 112.03,
        "unit": "$",
        "metric_type": "currency",
        "context": "(01/20/2025)</td><td>DKr 783.60</td></tr><tr><td>Diageo PLC (DEON)</td><td>U (07/20/2023)</td><td>US$112.03</td></tr><tr><td>Diageo PLC (DGE.L)</td><td>U (07/20/2023)</td><td>2,063p</td></tr><tr><td>H",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "42f3e8f4746ad87d",
        "value": 69.72,
        "unit": "€",
        "metric_type": "currency",
        "context": "U (07/20/2023)</td><td>2,063p</td></tr><tr><td>Heineken NV (HEIN.AS)</td><td>E (10/11/2023)</td><td>€69.72</td></tr><tr><td>Pernod Ricard SA (PER.PPA)</td><td>E (07/20/2023)</td><td>€100.40</td></tr><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "2ba6cb1876eb0c92",
        "value": 100.4,
        "unit": "€",
        "metric_type": "currency",
        "context": "/11/2023)</td><td>€69.72</td></tr><tr><td>Pernod Ricard SA (PER.PPA)</td><td>E (07/20/2023)</td><td>€100.40</td></tr><tr><td>Tilly Eno</td><td></td><td></td></tr><tr><td>Davide Campari Milano NV (CPRI",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "51498f3c1d460e63",
        "value": 6.57,
        "unit": "€",
        "metric_type": "currency",
        "context": "td><td></td><td></td></tr><tr><td>Davide Campari Milano NV (CPRI.MI)</td><td>E (08/12/2025)</td><td>€6.57</td></tr><tr><td>Remy Cointreau SA (RCOPPA)</td><td>U (07/22/2025)</td><td>€54.65</td></tr></t",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "fd11d0bc1b0894fc",
        "value": 54.65,
        "unit": "€",
        "metric_type": "currency",
        "context": "8/12/2025)</td><td>€6.57</td></tr><tr><td>Remy Cointreau SA (RCOPPA)</td><td>U (07/22/2025)</td><td>€54.65</td></tr></table> Stock Ratings are subject to change. Please see latest research for each co",
        "provenance": {
          "page": 7
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 2,
      "tables_count": 0,
      "numerical_data_count": 41,
      "passages_count": 77,
      "entities_count": 20
    }
  }
}